Invivo Capital

Invivo Partners is a venture capital firm specializing in early-stage companies within the life sciences sector, with a particular focus on biotechnology and the intersection of artificial intelligence (AI) and deep technology. The firm actively seeks projects demonstrating strong proof of concept, unique technological platforms, and disruptive products that offer first-in-class or first-in-modality potential. Their investment strategy targets companies developing innovative drugs, advanced therapies, and synthetic biology solutions, alongside AI-driven companies addressing real-world problems across various sectors, including healthcare, robotics, aerospace, mobility, computing, and climate.

The firm was co-founded in 2012 by Dr. Luis Pareras and Albert Ferrer, building upon the experience gained from their first fund, Healthequity. Laura Rodríguez later joined as a Partner, and more recently, Pep Martorell was welcomed as a Partner, further strengthening the firm's expertise in technology transfer and AI. Invivo Partners aims to become a leading player in Europe's biotech industry by leveraging its deep understanding of technology transfer and market trends. The firm's investor base includes significant institutional investors such as the European Investment Fund, Instituto de Crédito Oficial (ICO), Institut Català de Finances (ICF), Institut Valencià de Finances (IVF), and the Barcelona City Council, alongside a majority of private investors.

Invivo Partners has built a robust portfolio of over 17 companies and has achieved 4 successful exits. Notable investments include Minoryx Therapeutics, which focuses on therapies for severe orphan genetic diseases of the central nervous system; Sanifit Therapeutics, dedicated to treatments for progressive vascular calcification disorders, which was acquired by Vifor Pharma; and Peptomyc, developing a new generation of cell-penetrating peptides for cancer treatment. Other portfolio companies mentioned in recent news include Arthex Biotech, Gyala Therapeutics, and Integra Therapeutics, primarily in drug discovery and healthcare innovation. The firm's portfolio companies have collectively raised over €450 million from global venture capital firms.

The Invivo Partners team combines extensive scientific, technical, and financial expertise, enabling them to make impactful investments and foster significant growth within the health sector. The partners, including Luis Pareras, Albert Ferrer, Laura Rodríguez, and Pep Martorell, bring diverse backgrounds in venture capital, biotechnology, oncology gene therapy research, and technology transfer. This multidisciplinary approach allows the firm to provide strategic guidance and operational support to its portfolio companies, helping them navigate the complexities of drug development and market entry.